An international trial, run in the UK by researchers at the CRUK Southampton Clinical Trials Unit (SCTU) at the Centre for Cancer Immunology, has found that an intensive combination of chemotherapy and immunotherapy can dramatically improve survival for some patients with a rare blood cancer that typically have a very poor outlook.
Copy and paste this URL into your WordPress site to embed
